# Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

> **NCT05385926** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 34 (estimated)

## Conditions studied

- Metastatic Nasopharyngeal Cancer

## Interventions

- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05385926
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-05
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05385926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05385926, "Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05385926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*